However, inhibiting GCN5 could be a positive therapeutic strategy for treating acute lymphoblastic leukemia by reducing the levels of the E2A-PBX1 oncoprotein (Holmlund et al., 2013). The gene discussed is PBX1; the disease is acute lymphoblastic leukemia.